The findings of a new study support the development of Incyte‘s parsaclisib as a potential therapy for Sjögren’s syndrome and other autoimmune diseases. Parsaclisib, an oral inhibitor of phosphatidylinositol 3-kinase (PI3K) delta, was found to ease the symptoms of Sjögren’s and other disorders in a study using mouse models.

Current studies investigating treatment strategies for children with Sjögren’s syndrome have poor quality evidence for the development of clinical recommendations, a recent study has found. As such, these children are still prescribed medication based on their doctors’ opinions, not on evidence-based treatment recommendations. “Future research is required to guide…

Rituximab safely and effectively treated sudden interstitial lung disease (ILD) in a 49-year-old man with undiagnosed primary Sjögren’s syndrome, a case study shows. This case adds to a growing number of reports and case series showing that rituximab lessens lung involvement in Sjögren’s patients, further supporting the usefulness…